LIF and myeloid sarcoma: The first observation that raised hopes for neurotrophic factors as potential therapeutic agents in MS was finding that leukaemia inhibitory factor (LIF), belonging to the neurotrophic factor family, reduced clinical severity and promoted oligodendrocyte survival in mice suffering from an animal equivalent of MS, namely experimental autoimmune encephalomyelitis [41].